AVBP Stock Price Prediction

The radar chart shows that buying Arrivent Biopharma Inc (AVBP.O) stock in January has the highest probability of a positive return (100.00%), while February has the lowest probability (0.00%).

AVBP's stock price rose by 33.20% in 2024,decreased by -30.51% in 2025, and went by in

Bullish technical signals of AVBP include: STOCHk_14_3_3 < 20, CCI_20_0.015 < -100, WILLR_14 < -80.

Bearish technical signals of AVBP include: AO_5_34 < 0, MOM_10 < 0, MACD_12_26_9 < 0, Price crosses below 5-day SMA.

AVBP has 3 buy signals and 4 sell signals now. Overall the technical rating for AVBP is Neutral . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of AVBP.

Arrivent Biopharma Inc's overall moving average trend leans more bearish as of August 07 2025, with 4 negative signals and 0 positive signal.

The price prediction chart for Arrivent Biopharma Inc (AVBP.O) stock, as of August 03 2025, forecasts a -18.68% change over the next month, based on its high correlation with AYRO stock patterns. The similarity between their price movements over the analyzed periods is 94.81%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.

### **Price Prediction for AVBP Stock in 2025** ArriVent BioPharma (AVBP) is expected to reach a price target of **$37** by 2025, driven by its lead drug candidate firmonertinib's promising clinical results and strong analyst sentiment. The stock could potentially rise to **$45** if the Phase 3 clinical trials for firmonertinib are successful, positioning it as a superior treatment for NSCLC patients. This prediction is supported by B. Riley Securities' Buy rating and Guggenheim's optimistic outlook on the company's pipeline.

### **Price Prediction for AVBP Stock by 2030** Based on the analysis of AVBP's fundamentals and market trends, here is the price prediction for AVBP stock by 2030: 1. **Price Target**: $37 - **Reason**: B. Riley Securities has initiated coverage on AVBP with a Buy rating and a price target of $37, citing the potential of its lead drug candidate firmonertinib in treating non-small cell lung cancer (NSCLC) with specific mutations. The analyst estimates a potential market size of ~$700 million/year for this indication, positioning AVBP favorably in the biopharma sector. 2. **Market Potential**: - Firmonertinib is currently in Phase 3 trials for NSCLC patients with EGFR exon 20 insertion mutations and is also being studied in a Phase 1b trial for EGFR PACC mutations. The drug's ability to penetrate the brain and its oral administration could make it a superior treatment option compared to existing therapies. 3. **Valuation and Financial Health**: - AVBP ended 2024 with $266.5 million in cash, providing a strong financial foundation to support its clinical trials and operations. The company has no debt, reducing financial risks and making it an attractive investment for growth-focused investors. 4. **Technical Analysis**: - AVBP's stock is currently trading at $23.60, with a relative strength index (RSI) of 69.60, indicating it is in the upper range but not yet overbought. The stock is also trading near the upper Bollinger Band, suggesting potential volatility in the short term. 5. **Analyst Sentiment**: - Analysts are bullish on AVBP due to its promising pipeline and strong cash position. The lack of debt and the potential for firmonertinib to address a significant unmet medical need further supports the positive outlook. ### **Conclusion** AVBP stock is expected to reach $37 by 2030, driven by the potential success of firmonertinib and its strong financial position. Investors should monitor clinical trial progress and market expansion for further upside.